Stealth BioTherapeutics' filing for rare disease drug elamipretide has been turned down by the FDA, although the company says the US regulator has given it a "path forward" for the programme.
Generic drugmaker Viatris has become the first company to secure FDA approval for a biosimilar product that is considered completely interchangeable with the reference product – namely Sanofi's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback